TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN HODGKIN LYMPHOMA
Objective. The purpose of the review consisted in informing physicians of various specialties on recently obtained results of treatment using the technology of the hematopoietic stem cells transplantation in one of the most common neoplasms of the hematopoietic system - Hodgkin's lymphoma - in the leading clinics of the world and in the Republic of Belarus. Materials and methods. In 1979, it was noted for the first time that response to first-line chemotherapy in patients with Hodgkin lymphoma has a prognostic value for the subsequent treatment. In 1992, researchers from the USA National Cancer Institute analyzed the data of a long-term observation for the results of treatment of patients with Hodgkin's lymphoma in whom use of the first-line chemotherapy was not effective. All patients of this category were divided into 3 groups: 1) those with primary-progressive form of Hodgkin's lymphoma; 2) those with early relapse; 3) those with late relapse. Therapeutic approaches to these patients management include use of the second-line chemotherapy and of the high-dose chemotherapy with autologous transplantation of hematopoietic stem cells. In recent years, for the purpose other treatment methods such as sequential high-dose chemotherapy, allogeneic transplantation with hematopoietic stem cells, transplantation of allogeneic hematopoietic cells with not myeloablative conditioning (mini-transplantation) are used as well. Results. Application of modern methods of Hodgkin's lymphoma treatment allow cure more than 70% of patients. However, in cases refractory to the cytotoxic therapy or the disease relapse the standard chemotherapy potential is limited. Conclusion. Use of the high-dose chemotherapy with transplantation of hematopoietic stem cells allows achieving success in managing patients when the chemotherapy has yielded unsatisfactory results.